Shan has a track record of commercializing disruptive genomics and diagnostic technologies. She led U.S. market entry and revenue growth for spatial transcriptomics at Complete Genomics and drove oncology marketing and medical affairs strategies at Illumina and Invitae. Shan’s experience spans business development, AI-driven analytics, and startup valuation. Shan holds a Ph.D. in Biochemistry from Penn State and an MBA from Wharton. With nearly 100 publications and deep ties to KOLs and scientific networks, Shan brings sharp technical diligence and strategic insight to early-stage health-tech investments.